67
Participants
Start Date
February 28, 2011
Primary Completion Date
January 31, 2012
Study Completion Date
January 31, 2012
NNC109-0012
The subjects will receive 12 weekly doses of 3 mg/kg of NNC109-0012 administered subcutaneously (under the skin)
placebo
The subjects will receive 12 weekly doses of 3 mg/kg of Placebo administered subcutaneously (under the skin)
Novo Nordisk Investigational Site, Berlin
Novo Nordisk Investigational Site, A Coruña
Novo Nordisk Investigational Site, Santiago de Compostela
Novo Nordisk Investigational Site, Pavia
Novo Nordisk Investigational Site, Seville
Novo Nordisk Investigational Site, Mainz
Novo Nordisk Investigational Site, Würzburg
Novo Nordisk Investigational Site, Ploieşti
Novo Nordisk Investigational Site, Târgovişte
Novo Nordisk Investigational Site, Cluj-Napoca
Novo Nordisk Investigational Site, Brăila
Novo Nordisk Investigational Site, Brno
Novo Nordisk Investigational Site, Prague
Novo Nordisk Investigational Site, Prague
Novo Nordisk Investigational Site, Uherské Hradiště
Novo Nordisk Investigational Site, Zlín
Novo Nordisk Investigational Site, Bialystok
Novo Nordisk Investigational Site, Bialystok
Novo Nordisk Investigational Site, Bydgoszcz
Novo Nordisk Investigational Site, Bytom
Novo Nordisk Investigational Site, Elblag
Novo Nordisk Investigational Site, Gmina Końskie
Novo Nordisk Investigational Site, Poznan
Novo Nordisk Investigational Site, Żyrardów
Novo Nordisk Investigational Site, Lisbon
Novo Nordisk Investigational Site, Barcelona
Novo Nordisk Investigational Site, Cambridge
Novo Nordisk Investigational Site, Leeds
Novo Nordisk Investigational Site, Norwich
Lead Sponsor
Novo Nordisk A/S
INDUSTRY